We play an active role in breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Our team produces media releases, reports, policy papers and other informative content to keep you up to date on the most pressing issues facing our industry. Here in our resources section, you’ll find our most recent work.
This study examines the contribution of Canada’s research and development (R&D) pharmaceutical sector to the Canadian economy in 2022. It builds upon the annual reports produced since 2018.
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (736 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
More than 23-million Canadians depend on access to medicines and vaccines through employer-sponsored private plans.
Use this tool to search for brand name drugs to view their current negotiation status.
Learn more about the negotiation process from the pCPA.
One of Innovative Medicines Canada’s guiding principles is to offer solutions to challenges in the Canadian health system. Access to new medicines is one such challenge.
Use this beginner’s guide to understand the basics of how our industry works.
Everything you need to make an informed decision about our industry.
Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Informative content to keep you up to date on the most pressing issues facing our industry.
